增长分化因子15 - - 炎症性肠病中的新分子标:进展与挑战
Jia Yang1, Ya-Ting Pan1, Hong-Zhu Wen2
1Department of Oncology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
World journal of gastroenterology
|February 16, 2026
概括
增长分化因子15 (GDF15) 在炎症性肠病 (IBD) 中升高,增加了肠道透性. 准GDF15可能会保持肠道屏障的完整性,但需要进一步的研究才能临床应用.
科学领域:
- 胃肠道学和免疫学
- 分子和细胞生物学分子和细胞生物学
背景情况:
- 炎症性肠病 (IBD) 涉及复杂的免疫失调和受损的肠道屏障功能.
- 增长分化因子15 (GDF15) 是一种细胞因子,涉及各种生物过程,包括炎症和组织修复.
研究的目的:
- 调查GDF15在性结肠炎 (UC) 和克罗恩病 (CD) 发病过程中的作用.
- 确定GDF15对肠道屏障完整性的影响及其作为IBD治疗点的潜力.
主要方法:
- 在IBD患者和健康对照中分析循环GDF15水平.
- 使用结肠器官和T84细胞进行体内和体外研究,以评估GDF15对肠道透性的影响.
- 在对GDF15.15的反应中测量紧结蛋白表达 (ZO-1,claudin 1).
主要成果:
- 在UC和CD患者中观察到高GDF15水平,与炎症标志物相关.
- 研究人员发现,GDF15通过降低Zonula occludens-1 (ZO-1) 和Claudin 1的表达,增加了肠道的通透性.
- 这项研究使用了小样本,因此在解释时需要谨慎.
结论:
- GDF15可能在IBD中发挥双重作用,可能会加剧肠道屏障功能障碍.
- 向GDF15通过增强肠道屏障完整性,为IBD提供了一个潜在的治疗策略.
- 进一步的基因验证研究至关重要,以确认GDF15的作用及其在IBD治疗中的翻译潜力.
更多相关视频
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
915
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
915
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
795
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
795
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
600
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
600
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561